CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 13, 2004
Result type: Reports
Project Number: SR0012-000
Product Line: Reimbursement Review

Generic Name: Miglustat

Brand Name: Zavesca

Manufacturer: Actelion Pharmaceuticals Canada Inc.

Therapeutic Area: Gaucher disease

Indications: Gaucher disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 24, 2004

Recommendation Type: Do not list